Maximising the Therapeutic Potential of Complement Mediation Across Diverse Indications

Partner Content
Maximising the Therapeutic Potential of Complement Mediation Across Diverse Indications

Returning for its 9th year, the Complement-Based Drug Development Summit unites leading experts to tackle the industry's most pressing challenges. This includes exploring the use of complement-mediators as combination therapies, discovering innovative indications where complement inhibitors are being explored outside of the typical rare disease context, and unlocking novel methods being used to assess the safety and efficacy of complement inhibitors.

With insights from industry expert speakers such as Apellis, Complement Therapeutics, Sanofi, Annexon Biosciences, Argenx, and more, this summit is your comprehensive guide to defining your complement-based therapeutics strategy for 2026 and beyond. Delve into the immense opportunity presented by the next generation of life-changing therapeutics set to transform the lives of patients across hematology, ophthalmology, nephrology, oncology, and more.

Join Us For Interactive Discussions On:

  • Exploring Novel Efficacy & Safety Assessments: Delve into cutting-edge methods for evaluating complement inhibitor safety and efficacy, including case studies on complement imaging and the complement-neutrophil axis, featuring insights from Michael Holers and Annexon Biosciences
  • Discover Expanding Indications: Uncover innovative areas where complement inhibitors are being explored beyond rare diseases, such as Type 1 Diabetes, Cystic Fibrosis, and Neurodegeneration, with presentations from ArgenX and Invizius, as the field shifts its focus
  • Access Latest Clinical Readouts: Immerse yourself in the most recent clinical trial results for complement inhibitors across ophthalmology, nephrology, and hematology, with updates from Apellis, Annexon, and Sanegene Bio
  • Deep Dive into Intracellular Complement: Join Ben Afzali from NIH in a brand-new workshop exploring the next generation of therapeutic targets within intracellular complement and their effects on cellular metabolism, genetic regulation, and apoptosis
  • Uncover a New Complement Pathway Activator: Hear from Michael Brenner on his recent discovery of Granzyme K, which activates the entire complement system by cleaving C2 and C4 proteins, highlighting its promise as a future therapeutic target

Find out more here - https://ter.li/s5qzw7

CBDDS